Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ceva Sante Animale manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 5 pending office actions. These matters are distributed among several distinct examiners, showing a varied assignment of the company's legal matters. The prosecution activity is spread across 5 distinct art units, indicating a broad technical range for the pending applications within the Biotechnology & Pharmaceuticals sector.
The busiest examiner is MILLER, BETHANY MACKENZIE, who is responsible for 1 pending office action. This distribution indicates that each of the distinct examiners is handling exactly one of the company's pending matters across the various art units. This one-to-one ratio between examiners, art units, and pending actions suggests a highly diversified prosecution strategy where no two active matters are being reviewed by the same person. Such a spread across 5 distinct art units highlights the multifaceted nature of the company's current innovations. The 1 pending office action handled by MILLER, BETHANY MACKENZIE is part of this diverse portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| BROOKS, KREGG T | 1 | 57.1% | +1.5% |
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018526 | ACTINOBACILLUS PLEUROPNEUMONIAE VACCINES | DICKENS, AMELIA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030580 | METHOD FOR DETECTING CYSTOISOSPORA SUIS | SWITZER, JULIET CAROLINE | — |
| 18018526 | ACTINOBACILLUS PLEUROPNEUMONIAE VACCINES | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1764 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030580 | METHOD FOR DETECTING CYSTOISOSPORA SUIS | SWITZER, JULIET CAROLINE | 1682 | §103 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 18026566 | SURFACE-COATING FLUID COMPOSITION FOR ABSORBING AND DIFFUSING VOLATILE COMPOUNDS | BROOKS, KREGG T | 1764 | §103 | Final Rejection | 11d overdue | Pending | Mar 15, 2023 |
| 18018526 | ACTINOBACILLUS PLEUROPNEUMONIAE VACCINES | DICKENS, AMELIA NICOLE | 1645 | §103§112 | Non-Final OA | — | Pending | Jan 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCeva Sante Animale has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Juliet Caroline Switzer has the most, with 1 of Ceva Sante Animale's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
